Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
69High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06446960CT.gov The Role of Peripheral Afferents in Modulating Post-stroke Central Pain | — | Recruiting | — | — | — |
NCT05563571CT.gov Hemiplegic Shoulder Pain Management Using Shoulder pRF and Corticosteroid Injection | — | Unknown | — | — | — |
NCT05365880CT.gov Sphenopalatine Ganglion Block for the Treatment of Post-Stroke Headache | — | Withdrawn | — | — | — |
NCT05260125CT.gov Comparison of the Efficacy of Ultrasound Guided vs Non-guided Suprascapular Nerve Block Treatment in Stroke Patients | — | Recruiting | — | — | — |
NCT05589402CT.gov Temporary Inactivation of Strong Muscle Sensation to Improve Rehabilitation Interventions in SCI | — | Active Not Recruiting | — | — | — |
NCT03263117CT.gov SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke | — | Completed | — | — | — |
NCT02822144CT.gov General Anesthesia Versus Sedation During Intra-arterial Treatment for Stroke | — | Completed | — | — | — |
NCT02639806CT.gov General Anesthesia for Endovascular Thrombectomy; A Pilot Study. | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Stroke Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lidocaine (this asset) | Institut National de la Santé Et de la Recherche Médicale, France | Approved | BB · 67 |
| Incobotulinumtoxina | Parc de Salut Mar | P4 | BBB |
| Aggrenox | Boehringer Ingelheim | P4 | BBB |
| Atenolol | Northern California Institute of Research and Education | P4 | BBB |
| Dextromethorphan | University of Florida | P4 | BBB |
| Tenecteplase | Assistance Publique - Hôpitaux de Paris | P4 | BBB |
| Rivaroxaban | China National Center for Cardiovascular Diseases | P4 | BBB |
| Nerinetide | NoNO Inc. | P3 | BBB |
| Warfarin | China National Center for Cardiovascular Diseases | P4 | BB |
+42 more in the Stroke Disorder cohort
Other indications for Lidocaine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Peripheral Neuropathy | — | P4 | BBB · 79 |
| Postherpetic Neuralgia | — | P4 | BBB · 78 |
| Post-Operative Pain, Non-Human Animal | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Lidocaine in Stroke Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lidocaine-stroke-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →